Companion Diagnostic Patents

Companion diagnostic patents cover assay/platform innovations; biomarker-application (method) innovations; algorithm/scoring innovations; and drug-diagnostic co-development and sample/workflow innovations — with IP held by diagnostic companies and pharma co-development partners (in a field testing which patients should get which drug). WHY COMPANION DIAGNOSTICS: a COMPANION DIAGNOSTIC (CDx) is a TEST that identifies WHICH patients should — or should not — receive a particular DRUG, by detecting a BIOMARKER (a gene mutation, protein over-expression, fusion, etc.) that predicts whether the drug will WORK or cause HARM; CDx is the backbone of PRECISION/personalized MEDICINE — matching the right drug to the right patient (the HER2 test gates Herceptin; EGFR/ALK tests gate lung-cancer targeted therapies; BRCA gates PARP inhibitors) — and a CDx is co-developed and co-approved together WITH a specific drug, making it both a clinical necessity and a commercial partnership. THE CENTRAL IP ISSUE — §101: the CORRELATION between a biomarker and drug response is a NATURAL LAW/natural phenomenon, and after the Supreme Court's MAYO (natural laws) and MYRIAD (natural products/genes) decisions, such correlations are generally NOT patent-eligible under §101 — so you CANNOT patent 'the discovery that biomarker X predicts response to drug Y'; patentable IP must instead live in the specific TEST — the assay technology, novel detection methods, algorithms, and applications. MAJOR HOLDERS: ROCHE/VENTANA, AGILENT/DAKO, FOUNDATION MEDICINE, GUARDANT, QIAGEN, plus pharma co-development partners. Assay/platform, biomarker application (as method), algorithm/scoring, drug-diagnostic co-development, and sample/workflow are the core CDx patent domains — with §101 (Mayo/Myriad) the gate, and assays, methods, algorithms, and workflows the patentable whitespace.

Assay/platform innovations; biomarker-application (method) innovations; novel-detection innovations; and §101-aware claiming represent core CDx patent domains — and the specific test technology and carefully-claimed detection/treatment methods are the foundational, patentable capabilities (the natural correlation is not). ASSAY / PLATFORM PATENTS: the specific TEST TECHNOLOGY — the PCR assay, NEXT-GENERATION SEQUENCING (NGS) panel, IMMUNOHISTOCHEMISTRY (IHC) stain/antibody, FISH, or mass-spec method, plus the instrument, reagents, and KIT — used to detect the biomarker; assay/platform technology is core, PATENTABLE IP (a concrete assay/instrument/kit is a man-made technology, not a natural law — the most clearly §101-eligible CDx IP and the foundation of a diagnostic). BIOMARKER-APPLICATION (METHOD) PATENTS: rather than claiming the natural correlation (ineligible), claim a SPECIFIC, NOVEL DETECTION METHOD (a new technical way to measure the biomarker that transforms a sample/adds an inventive step beyond routine detection) or a METHOD OF TREATMENT (administering drug Y to a patient determined to have biomarker X) — both can be eligible if claimed correctly; biomarker-application methods are high-value IP BUT §101-CRITICAL (the Federal Circuit allows novel detection methods and treatment methods, but rejects 'observe-the-correlation' claims — claim drafting is everything). NOVEL-DETECTION PATENTS: genuinely new, inventive detection chemistries/techniques (not conventional/routine application of known methods — Mayo bars routine steps); novel-detection methods are high-value IP. §101-AWARE CLAIMING: NEVER claim the biomarker-response correlation itself (Mayo/Myriad natural law/product) — claim the assay, a novel detection method, a treatment method, or a specific technical improvement; §101-aware claiming is THE threshold skill for CDx IP (the difference between a valuable patent and an ineligible one). Assay/platform, biomarker-application methods, novel detection, and §101-aware claiming are the highest-value core IP because a concrete test technology and carefully-claimed novel methods are exactly what is patentable in a field where the underlying correlation is not.

Algorithm/scoring innovations; drug-diagnostic co-development innovations; sample/workflow innovations; and multi-biomarker/panel innovations represent additional CDx patent domains — and the interpretation software, the regulated drug partnership, and the lab process are where additional patentable value and commercial advantage lie. ALGORITHM / SCORING PATENTS: the COMPUTATIONAL interpretation — scoring algorithms, machine-learning CLASSIFIERS, image-analysis (for IHC/pathology), and the CUTOFFS/thresholds that turn raw test data into a positive/negative call or a quantitative score; algorithm/scoring methods are high-value IP BUT §101-SENSITIVE (a pure 'analyze data with a formula' claim is abstract — claim a specific technical implementation, an improvement to the testing system, or an integrated diagnostic workflow, not the abstract math). DRUG-DIAGNOSTIC CO-DEVELOPMENT PATENTS: the regulated CDx + drug CO-APPROVAL relationship — a CDx is developed alongside a specific drug and approved with it, creating commercial EXCLUSIVITY/partnership dynamics (pharma needs the test to sell the drug); co-development methods and the structured drug-test combination can carry IP, but much value here is in the PARTNERSHIP/regulatory position and CONTRACTS as much as patents (the FDA-approved CDx-drug pairing is a powerful commercial moat regardless of patent breadth). SAMPLE / WORKFLOW PATENTS: SAMPLE preparation, stabilization, extraction, and the LAB WORKFLOW (turnaround, automation, quality control) — concrete process steps; sample/workflow methods are PATENTABLE, valuable IP (a man-made process, clearly §101-eligible, and a real operational differentiator). MULTI-BIOMARKER / PANEL PATENTS: comprehensive NGS PANELS testing many biomarkers at once (Foundation/Guardant), and combining biomarkers into a signature/classifier; panel/signature methods are high-value IP (large panels and multi-marker classifiers are commercially dominant and offer more patentable, system-level claims). Algorithm/scoring, drug-diagnostic co-development, sample/workflow, and multi-biomarker panels are the highest-value application IP because interpretation software, the regulated drug partnership, lab process, and comprehensive panels are exactly what make a CDx commercially valuable — claimed around §101.

CDx startup IP strategy must navigate the §101 Mayo/Myriad constraint (the #1 issue — biomarker-drug-response correlations are natural laws and NOT patent-eligible; NEVER rely on correlation claims; build IP on the assay, novel detection methods, treatment methods, algorithms, panels, and workflow), the patent-vs-other-moats reality (because §101 weakens diagnostic patents, much of a CDx business's protection comes from the FDA-APPROVED drug-test PARTNERSHIP, regulatory exclusivity, proprietary data, lab/trade-secret know-how, and reimbursement, not just patents), the assay/platform foundation (concrete assay technology, instruments, and kits are the most clearly patentable IP), the pharma co-development model (a CDx is built with and approved alongside a specific drug — the partnership is both the business and a moat), the algorithm/§101 sensitivity (scoring/AI must be claimed as technical systems, not abstract math), the panel/NGS shift (comprehensive multi-biomarker panels dominate and offer more system-level IP), the regulatory/reimbursement reality (FDA approval and payer coverage drive value as much as patents), and a landscape where assays, methods, algorithms, panels, and workflows are the durable assets; understand that correlations are §101-barred, so the durable IP is in assay/platform technology, novel detection methods, treatment methods, scoring algorithms (as systems), multi-biomarker panels, and sample/workflow — with the drug partnership, FDA approval, proprietary data, assay technology, and lab know-how often the real moat (not patents), and that §101-survivable claiming, the drug partnership, regulatory/reimbursement, and clinical validity matter as much as patents; identify whitespace in assays, novel detection, panels, and algorithms. CDx STARTUP IP STRATEGY: ASSAY/PLATFORM, NOVEL DETECTION/TREATMENT METHODS, ALGORITHMS (AS SYSTEMS), PANELS, AND WORKFLOW ARE THE IP: patent the assay technology/kits, novel detection methods, treatment-selection methods, scoring algorithms (as technical systems), multi-biomarker panels, and sample/workflow — NOT the natural correlation; §101 (MAYO/MYRIAD) IS THE #1 GATE: biomarker-drug-response correlations are natural laws/products and ineligible — NEVER claim the correlation; claim the assay, a novel detection method, a treatment method, or a specific technical improvement (claim drafting is everything); ASSAY/PLATFORM IS THE MOST CLEARLY PATENTABLE IP: concrete assay technology, instruments, and kits are man-made and §101-eligible — the foundation; NON-PATENT MOATS ARE CENTRAL (BECAUSE §101 WEAKENS DX PATENTS): the FDA-approved drug-test PARTNERSHIP, regulatory exclusivity, proprietary data, lab/trade-secret know-how, and reimbursement protect a CDx business as much as patents; PHARMA CO-DEVELOPMENT IS THE BUSINESS + A MOAT: a CDx is co-developed/co-approved with a specific drug — pharma needs the test to sell the drug, a powerful commercial position; ALGORITHMS/AI ARE §101-SENSITIVE: claim scoring/AI as technical systems/workflow improvements, not abstract math; PANELS/NGS DOMINATE + OFFER SYSTEM-LEVEL IP: comprehensive multi-biomarker panels (Foundation/Guardant) are commercially dominant and more patentable; SAMPLE/WORKFLOW IS PATENTABLE PROCESS IP: man-made sample-prep/workflow steps are §101-eligible and a real differentiator; §101/PARTNERSHIP/REGULATORY/CLINICAL-VALIDITY MATTER AS MUCH AS PATENTS: §101-survivable claiming, the drug partnership, regulatory/reimbursement, and clinical validity drive value; WHEN TO PATENT (OR RELY ON OTHER MOATS): NOVEL ASSAY/METHOD/ALGORITHM/PANEL WITH MEASURED PERFORMANCE: file (and secure the drug partnership/data) once a test shows measured results (analytical/clinical validity — sensitivity/specificity + concordance + clinical-utility/patient-selection performance + §101-survivable claim framing) — analytical/clinical validity and §101-survivable claiming are the critical CDx IP metrics; KEY FTO CHECKLIST: Roche/Ventana, Agilent/Dako, Foundation Medicine, Guardant, Qiagen; §101 Mayo/Myriad (NEVER claim the correlation; claim assay/detection-method/treatment-method/technical-improvement); assay/platform (PCR/NGS/IHC/FISH/mass-spec, instrument/kit); biomarker application (novel detection method / treatment method); algorithm/scoring (classifier/cutoff/image-analysis — claim as system); drug-diagnostic co-development (FDA co-approval/partnership/exclusivity); sample/workflow (prep/stabilization/automation); multi-biomarker/NGS panel; regulatory/reimbursement; clinical validity/utility.